Anti-CTLA-4 immunotherapy effect on αSMA+ myofibroblast late-depleted pancreatic ductal adenocarcinoma model
Summary:
Analysis of pancreatic ductal adenocarcinoma (PDAC) tumors from PKT; αSMA-tk+ transgenics injected daily with ganciclovir at 6 weeks of age for 10 days or less to deplete αSMA+ myofibroblasts and treated with anti-CTLA4. Results provide insight into molecular basis of anti-CTLA4 therapy in PDAC.
Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014 Jun 16;25(6):719-34. PMID: 24856586
